Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

被引：6
作者：
Grant, H. [1 ]
Jiang, X. [2 ,3 ]
Stebbing, J. [4 ]
Foroni, L. [5 ]
Craddock, C. [6 ]
Griffiths, M. [7 ]
Clark, R. E. [8 ]
O'Brien, S. [9 ]
Khorashad, J. S. [5 ]
Gerrard, G. [5 ]
Wang, L. [8 ]
Irving, J. A. E. [9 ]
Wang, M. [10 ]
Karran, L. [11 ]
Dyer, M. J. S. [11 ]
Forrest, D. [12 ]
Page, K. [1 ]
Eaves, C. J. [2 ,3 ]
Woolfson, A. [13 ]
机构：
[1] UCL, Dept Math, London, England
[2] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada
[3] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[4] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med Oncol, London, England
[5] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med, London, England
[6] Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England
[7] Birmingham Womens NHS Fdn Trust, W Midlands Reg Genet Lab, Birmingham, W Midlands, England
[8] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England
[9] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[10] MRC, Mol Biol Lab, Div Prot & Nucle Acid Chem, Cambridge CB2 2QH, England
[11] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England
[12] British Columbia Canc Agcy, Div Hematol, Leukaemia BMT Program British Columbia, Vancouver, BC V5Z 4E6, Canada
[13] Bristol Myers Squibb Co, Discovery Med Oncol, Princeton, NJ USA
来源：
LEUKEMIA | 2010年 / 24卷 / 10期
基金：
英国医学研究理事会;
关键词：
RESISTANCE; MECHANISMS; INHIBITOR; IMATINIB;
D O I：
10.1038/leu.2010.179
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1817 / 1821
页数：5
相关论文
共 50 条
  • [41] BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib
    Benjamin, Esther Sathya Bama
    Ravindra, Niveditha
    Rajamani, Bharathi Murugan
    Anandan, Senthamizhselvi
    Kausalya, Bagavathi
    Veldore, Vidya
    Mathews, Vikram
    Velayudhan, Shaji Ramachandran
    Balasubramanian, Poonkuzhali
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1528 - 1531
  • [42] Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib
    Rostami, Golale
    Hamid, Mohammad
    Yaran, Majid
    Khani, Mohsen
    Karimipoor, Morteza
    [J]. JOURNAL OF HUMAN GENETICS, 2015, 60 (05) : 253 - 258
  • [43] Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
    Burslem, George M.
    Schultz, Anna Reister
    Bondeson, Daniel P.
    Eide, Christopher A.
    Stevens, Samantha L. Savage
    Druker, Brian J.
    Crews, Craig M.
    [J]. CANCER RESEARCH, 2019, 79 (18) : 4744 - 4753
  • [44] BCR-Abl Silencing by siRNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy
    Remant, K. C.
    Thapa, Bindu
    Ubeda, Anyeld
    Jiang, Xiaoyan
    Uludag, Hasan
    [J]. STEM CELLS AND DEVELOPMENT, 2019, 28 (11) : 734 - 744
  • [45] Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells
    Fan, Jiajun
    Dong, Xiaochun
    Zhang, Weixing
    Zeng, Xian
    Li, Yubin
    Sun, Yun
    Wang, Shaofei
    Wang, Ziyu
    Gao, Hongjian
    Zhao, Weili
    Ju, Dianwen
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2014, 98 (23) : 9763 - 9775
  • [46] Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
    Chen, Kangkang
    Ruan, Yingying
    Tian, Kewei
    Xiong, Peisheng
    Xia, Nan
    Li, Jin
    Huang, Wen
    Cao, Feiyan
    Chen, Qifeng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells
    Than, Hein
    Pomicter, Anthony D.
    Yan, Dongqing
    Beaver, Larry P.
    Eiring, Anna M.
    Heaton, William L.
    Senina, Anna
    Clair, Phillip M.
    Shacham, Sharon
    Mason, Clinton C.
    O'Hare, Thomas
    Deininger, Michael W.
    [J]. LEUKEMIA, 2020, 34 (06) : 1679 - 1683
  • [48] BAFETINIB Dual BCR/ABL and Lyn Tyrosine Kinase Inhibitor Treatment of Chronic Myeloid Leukemia
    Takeuchi, M.
    Kimura, S.
    Ashihara, E.
    Maekawa, T.
    [J]. DRUGS OF THE FUTURE, 2009, 34 (04) : 261 - 269
  • [49] MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression
    Chen Huan
    Lou Jin
    Wang Heng
    An Na
    Pan Yuming
    Du Xin
    Zhang Qiaoxia
    [J]. LEUKEMIA RESEARCH, 2018, 75 : 1 - 6
  • [50] Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
    Baccarani, Michele
    Rosti, Gianantonio
    Soverini, Simona
    [J]. LEUKEMIA, 2019, 33 (10) : 2358 - 2364
12345